LONG-TERM CLINICAL OUTCOME OF A REAL WORLD EXPERIENCE IN PATIENTS TREATED WITH A GENOUSTM EPC CAPTURING STENT  by Klomp, Margo et al.
    
 i2 SUMMIT   
A180.E1683 
JACC March 9, 2010
Volume 55, issue 10A
LONG-TERM CLINICAL OUTCOME OF A REAL WORLD EXPERIENCE IN PATIENTS TREATED WITH A 
GENOUSTM EPC CAPTURING STENT
i2 Oral Contributions
Georgia World Congress Center, Room B315
Sunday, March 14, 2010, 5:18 p.m.-5:30 p.m.
Session Title: New Technologies
Abstract Category: New Technologies/Innovations
Presentation Number: 2904-09
Authors: Margo Klomp, Marcel A. Beijk, Karel T. Koch, Jose P. Henriques, Jan Baan, Marije M. Vis, Jan G. Tijssen, Jan J. Piek, Robbert J. de Winter, 
Academic Medical Center-University of Amsterdam, Amsterdam, The Netherlands
Background The occurrence of repeat revascularization and stent thrombosis (ST) remains a problem, even in the drug-eluting stent (DES) era. 
The novel Genous™ endothelial progenitor cell (EPC)-capturing stent is coated with CD34+ antibodies that bind circulating EPCs to the stent 
surface, thereby accelerating endothelialization of the stent struts. To date, no study has been performed evaluating the 1-year clinical outcome in a 
population of unselected patients treated with the EPC-capturing stent.
Methods Between September 2005 and February 2008, a total of 405 “real-world” patients were treated with the EPC capturing stent. Dual anti-
platelet therapy (DAPT) was prescribed for 1 month. Clinical follow-up was obtained at 1 year.
Results Mean age of the population was 63±11 years, 72% were male, and 18% were diabetic patients. Sixteen patients had a contra-indication 
for treatment with a DES, receiving only 2 weeks of clopidogrel post-angioplasty. A total of 510 lesions were treated with the EPC-capturing stent. 
Of these lesions, 75% were type B2/C lesions according to ACC/AHA classification, 20% were CTOs and 24% were bifurcated lesions, reflecting daily 
practice. Mean stent length was 24.6±11.7 mm and mean stent diameter was 3.3±0.4 mm.
At 1-year clinical follow-up, the composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR) was 13.3%. Ten 
patients (2.5%) died of cardiac cause, and 11 suffered a MI of which 6 (1.5%) peri-procedural and 5 (1.2%) spontaneous. Clinically driven TLR was 
9.1%, CABG was 1.7%. Definite ST was 0.5% occurring at 7 and 18 days respectively.
Conclusion In this single-center study, the one-year clinical follow-up in unselected patients carrying predominantly complex lesions treated with 
an EPC-capturing stent showed good results.  Furthermore, using this stent avoids the need for long-term DAPT.
